Rising geopolitical tensions, more broadly, have underscored the fragility of some business relationships. In the future, it seems likely that supply chains will be shorter, more diversified and more resilient. Trade will likely narrow to more trusted partners. These changes will increase resilience but at the cost of efficiency. And through this adjustment, production costs could rise, increasing price pressures.
So, from time to time we learn that the Food and Drug Administration interrupts the sale of drugs that have been on the market for years, on the grounds provided by new evidence concerning previously unknown deleterious side effects.